Momendol (Naproxen)

Naproxen inhibits the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in peripheral tissues, which reduces the synthesis of prostaglandins—key mediators of inflammation and pain. By lowering prostaglandin levels at the site of application, the drug diminishes swelling, pain signaling, and edema.

The specific dose and frequency of Momendol are determined by the prescribing healthcare professional based on the severity of the condition, the size of the treatment area, and individual patient factors. Patients should follow the prescriber’s instructions and the product label carefully.

Safety of topical naproxen during pregnancy or lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using Momendol.

To place an order, submit an enquiry on the Momendol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Momendol (naproxen) and other topical NSAIDs such as ibuprofen or diclofenac share a similar mechanism of cyclooxygenase inhibition. Naproxen generally offers a longer duration of action, which may allow less frequent application, while ibuprofen may be preferred for patients with specific sensitivities. Choice depends on clinical response, tolerability, and physician preference.

Momendol should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and excessive heat. Ensure the container is tightly closed when not in use to maintain stability.

Momendol is applied topically to clean, dry skin over the affected area. The prescribed amount is spread in a thin layer and gently massaged until absorbed. Hands should be washed after application, and the treated skin should not be covered with occlusive dressings unless directed by a healthcare professional.

Serious risks include severe allergic reactions such as rash, swelling, or Stevens‑Johnson syndrome, as well as systemic effects like gastrointestinal bleeding, renal impairment, and cardiovascular events. Patients should seek immediate medical attention if they experience signs of a serious reaction.

Momendol should be avoided by individuals with known hypersensitivity to naproxen or any component of the formulation, those with active gastrointestinal ulcers, severe renal or hepatic impairment, and patients taking anticoagulants or other NSAIDs without medical guidance. Pregnant or breastfeeding women should consult a physician before use.